(Q38003346)

26 August 2017

title

Clinical utility of interleukin-28B testing in patients with genotype 1. (English)

1 reference

26 August 2017

Nezam H Afdhal

2

0 references

author name string

Michelle Lai

series ordinal

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

56

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

367-372

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

26 August 2017

cites work

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients

21 January 2018

1 reference

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C

21 January 2018

1 reference

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

21 January 2018

1 reference

Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

21 January 2018

1 reference

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

21 January 2018

1 reference

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

21 January 2018

1 reference

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.

21 January 2018

1 reference

Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.

21 January 2018

1 reference

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.25793

1 reference

26 August 2017

1 reference